blebbistatin profile

(S)-blebbistatin : The (S)-enantiomer of blebbistatin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	5287792
CHEMBL ID	1231358
CHEBI ID	75388
SCHEMBL ID	4330341
MeSH ID	M0447664

Synonym
CHEMBL1231358 ,
chebi:75388 ,
(-)-1-phenyl-1,2,3,4-tetrahydro-4-hydroxypyrrolo[2,3-b]-7-methylquinolin-4-one
(s)-blebbistatin
DB01944
NCGC00092288-02
NCGC00092288-01
SCHEMBL4330341
(3as)-3a-hydroxy-6-methyl-1-phenyl-2,3-dihydropyrrolo[2,3-b]quinolin-4-one
(3as)-3a-hydroxy-6-methyl-1-phenyl-1,2,3,3a-tetrahydro-4h-pyrrolo[2,3-b]quinolin-4-one
unii-8wii7624i5
8wii7624i5 ,
(-)-blebbistatin ,
blebbistatin (s)-form [mi]
4h-pyrrolo(2,3-b)quinolin-4-one, 1,2,3,3a-tetrahydro-3a-hydroxy-6-methyl-1-phenyl-, (3as)-
blebbistatin, (-)-
856925-71-8
(s)-(-)-blebbistatin
S7099
CS-4983
HY-13441
(s)-3a-hydroxy-6-methyl-1-phenyl-3,3a-dihydro-1h-pyrrolo[2,3-b]quinolin-4(2h)-one
(3as)-(-)-1,2,3,3a-tetrahydro-3a-hydroxy-6-methyl-1-phenyl-4h-pyrrolo[2,3-b]quinolin-4-one
DTXSID70415329
1,2,3,3a-tetrahydro-3as-hydroxy-6-methyl-1-phenyl-4h-pyrrolo[2,3-b]quinolin-4-one
AKOS024456817
HMS3648O21
mfcd08460907
(-)-blebbistatin, solid, synthetic
EX-A703
HMS3653A05
F17375
(-)blebbistatin
NCGC00092288-05
SW219535-1
Q27093043
SR-01000946255-1
sr-01000946255
BCP09979
(s)-3a-hydroxy-6-methyl-1-phenyl-1,2,3,3a-tetrahydro-4h-pyrrolo[2,3-b]quinolin-4-one
HMS3674I13
blebbistatin-(-)
blebbistatin-(+/-)
CCG-267396
AS-57305
(3as)-3a-hydroxy-6-methyl-1-phenyl-1h,2h,3h,3ah,4h-pyrrolo[2,3-b]quinolin-4-one
AC-35899
BB181114
bdbm50546882

Excerpt	Reference	Relevance
"(S)-Blebbistatin is a widely used research tool to study myosin II, an important regulator of many motility based diseases. "	( Improved synthesis and comparative analysis of the tool properties of new and existing D-ring modified (S)-blebbistatin analogs. Bracke, ME; Roman, BI; Stevens, CV; Verhasselt, S, 2017)	1.23
"(S)-Blebbistatin is a known micromolar inhibitor of this protein."	( Insights into the myosin II inhibitory potency of A-ring-modified (S)-blebbistatin analogs. Bracke, ME; Roman, BI; Stevens, CV; Van den Broecke, T; Verhasselt, S, 2017)	1.17
"(S)-Blebbistatin is a micromolar myosin II ATPase inhibitor that is extensively used in research. "	( Synthesis of C-ring-modified blebbistatin derivatives and evaluation of their myosin II ATPase inhibitory potency. De Wever, O; Mangodt, CW; Roman, BI; Stevens, CV; Verhasselt, S, 2018)	1.33

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Class	Description
blebbistatin	A pyrroloquinoline that is 1,2,3,3a-tetrahydro-H-pyrrolo[2,3-b]quinolin-4-one substituted by a hydroxy group at position 3a, a methyl group at position 6 and a phenyl group at position 1. It acts as an inhibitor of ATPase activity of non-muscle myosin II.
tertiary alpha-hydroxy ketone	An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (30)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	39.8107	0.1778	14.3909	39.8107	AID2147
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	42.8000	5.6234	17.2929	31.6228	AID485281
15-lipoxygenase, partial	Homo sapiens (human)	Potency	31.6228	0.0126	10.6917	88.5700	AID887
Microtubule-associated protein tau	Homo sapiens (human)	Potency	7.0795	0.1800	13.5574	39.8107	AID1460
EWS/FLI fusion protein	Homo sapiens (human)	Potency	13.9958	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
hemoglobin subunit beta	Homo sapiens (human)	Potency	31.6228	0.3162	9.0861	31.6228	AID925
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	12.5893	0.0316	10.2792	39.8107	AID884; AID885
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	22.3872	0.2512	15.8432	39.8107	AID504327
caspase-1 isoform alpha precursor	Homo sapiens (human)	Potency	31.6228	0.0003	11.4484	31.6228	AID900
lethal factor (plasmid)	Bacillus anthracis str. A2012	Potency	25.1189	0.0200	10.7869	31.6228	AID912
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Caspase-7	Homo sapiens (human)	Potency	31.6228	3.9811	18.5856	31.6228	AID889
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	0.4000	0.0000	2.0151	10.0000	AID1676132
Myosin-2	Bos taurus (cattle)	IC50 (µMol)	2.3000	2.3000	2.3000	2.3000	AID1676134
Myosin-2	Sus scrofa (pig)	IC50 (µMol)	0.4000	0.4000	0.4000	0.4000	AID1676132
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (33)

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
proteolysis	Caspase-7	Homo sapiens (human)
apoptotic process	Caspase-7	Homo sapiens (human)
heart development	Caspase-7	Homo sapiens (human)
response to UV	Caspase-7	Homo sapiens (human)
protein processing	Caspase-7	Homo sapiens (human)
protein catabolic process	Caspase-7	Homo sapiens (human)
defense response to bacterium	Caspase-7	Homo sapiens (human)
fibroblast apoptotic process	Caspase-7	Homo sapiens (human)
striated muscle cell differentiation	Caspase-7	Homo sapiens (human)
neuron apoptotic process	Caspase-7	Homo sapiens (human)
protein maturation	Caspase-7	Homo sapiens (human)
lymphocyte apoptotic process	Caspase-7	Homo sapiens (human)
cellular response to lipopolysaccharide	Caspase-7	Homo sapiens (human)
cellular response to staurosporine	Caspase-7	Homo sapiens (human)
execution phase of apoptosis	Caspase-7	Homo sapiens (human)
positive regulation of plasma membrane repair	Caspase-7	Homo sapiens (human)
positive regulation of neuron apoptotic process	Caspase-7	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Process	via Protein(s)	Taxonomy
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
RNA binding	Caspase-7	Homo sapiens (human)
aspartic-type endopeptidase activity	Caspase-7	Homo sapiens (human)
cysteine-type endopeptidase activity	Caspase-7	Homo sapiens (human)
protein binding	Caspase-7	Homo sapiens (human)
peptidase activity	Caspase-7	Homo sapiens (human)
cysteine-type peptidase activity	Caspase-7	Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic process	Caspase-7	Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosis	Caspase-7	Homo sapiens (human)
calmodulin binding	Myosin-2	Bos taurus (cattle)
ATP binding	Myosin-2	Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Process	via Protein(s)	Taxonomy
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
extracellular space	Caspase-7	Homo sapiens (human)
nucleus	Caspase-7	Homo sapiens (human)
cytoplasm	Caspase-7	Homo sapiens (human)
cytosol	Caspase-7	Homo sapiens (human)
nucleus	Caspase-7	Homo sapiens (human)
nucleoplasm	Caspase-7	Homo sapiens (human)
cytosol	Caspase-7	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
myofibril	Myosin-2	Bos taurus (cattle)
sarcomere	Myosin-2	Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (113)

Assay ID	Title	Year	Journal	Article
AID1693699	Antimigratory activity against human MDA-MB-231 cells assessed as minimum effective concentration by light microscopy	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	In vitro and in vivo effects of inhibitors on actin and myosin.
AID1360407	Phototoxicity against human HeLa cells assessed as cell death at 20 uM in presence of light irradiation at 480 +/- 10 nm for 15 mins measured after 3 days by trypan blue based light microscopy relative to control	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives.
AID1506919	Apparent permeability from basolateral to apical side in human Caco2 cells at 10 uM after 40 mins by HPLC-MS/MS analysis	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Improved synthesis and comparative analysis of the tool properties of new and existing D-ring modified (S)-blebbistatin analogs.
AID1360409	Toxicity in zebrafish embryo assessed as mortality at 10 uM in presence 0.4 uJ/cm2 of irradiation measured after 36 hrs relative to control	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives.
AID1577035	Activation of rabbit skeletal muscle actin thin filament complex-stimulated myosin S1 ATPase activity assessed as inorganic phosphate liberated at 100 uM incubated for 10 mins in presence of ATP by spectrophotometry relative to control	2019	Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18	Design and synthesis of sulfonamidophenylethylamides as novel cardiac myosin activator.
AID1693688	Inhibition of rabbit muscle F-actin depolymerization at 50 to 100 uM incubated for 15 mins by spectrophotometric analysis	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	In vitro and in vivo effects of inhibitors on actin and myosin.
AID1577038	Activation of chicken gizzard muscle actin and tropomyosin-stimulated myosin S1 ATPase activity assessed as inorganic phosphate liberated at 100 uM incubated for 10 mins in presence of ATP by spectrophotometry relative to control	2019	Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18	Design and synthesis of sulfonamidophenylethylamides as novel cardiac myosin activator.
AID1360401	Cytotoxicity against human LNCAP cells assessed as cell death at 200 uM after 24 hrs relative to control	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives.
AID1360397	Cytotoxicity against human U87 cells assessed as cell death at 200 uM after 24 hrs relative to control	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives.
AID1402186	Activation of actin-stimulated chicken gizzard smooth muscle myosin S1 fragment ATPase activity at 100 uM after 10 mins by spectrophotometric analysis relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design and synthesis of sulfonamidophenylethylureas as novel cardiac myosin activator.
AID1676138	Binding affinity to skeletal myosin S1 (unknown origin) assessed as fluorescence intensity in presence of ATP	2020	Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19	Synthesis and Evaluation of 4-Hydroxycoumarin Imines as Inhibitors of Class II Myosins.
AID1693696	Antimigratory activity against human MDA-MB-231 cells assessed as cell migration at 5 uM by light microscopy relative to control	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	In vitro and in vivo effects of inhibitors on actin and myosin.
AID1497387	Inhibition of rabbit skeletal muscle myosin 2 ATPase in presence of F-actin after 1 hr	2018	Bioorganic & medicinal chemistry letters, 07-15, Volume: 28, Issue:13	Synthesis of C-ring-modified blebbistatin derivatives and evaluation of their myosin II ATPase inhibitory potency.
AID1360411	Cytotoxicity against human BxPC3 cells assessed as cell death at 400 uM after 24 hrs	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives.
AID1506917	Aqueous solubility at steady-state in pH 7.4 PBS at 200 uM after 24 hrs by HPLC method	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Improved synthesis and comparative analysis of the tool properties of new and existing D-ring modified (S)-blebbistatin analogs.
AID1453496	Solubility of the compound in Tris-HCl at pH 7.5	2017	Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13	Insights into the myosin II inhibitory potency of A-ring-modified (S)-blebbistatin analogs.
AID1360412	Cytotoxicity against human Capan2 cells assessed as cell death at 400 uM after 24 hrs	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives.
AID1360398	Cytotoxicity against human U87 cells assessed as cell death at 200 uM after 3 hrs relative to control	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives.
AID1506922	Photostability of the compound in PBS/MeOH at 20 uM under blue light irradiation at 488 nm assessed as compound degradation after 30 mins by fluorescence spectroscopic analysis	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Improved synthesis and comparative analysis of the tool properties of new and existing D-ring modified (S)-blebbistatin analogs.
AID1360406	Cytotoxicity against human Fem-X cells assessed as cell death at 200 uM after 3 hrs relative to control	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives.
AID1360399	Cytotoxicity against human DU145 cells assessed as cell death at 200 uM after 24 hrs relative to control	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives.
AID1360402	Cytotoxicity against human LNCAP cells assessed as cell death at 200 uM after 3 hrs relative to control	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives.
AID1360395	Steady state aqueous solubility of the compound in 0.1 % DMSO buffer at 25 degC	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives.
AID1676140	Inhibition of C57Bl6 mouse skeletal muscle myosin assessed as inhibition of phrenic nerve stimulation-induced contraction in mouse diaphragm at 100 uM relative to control	2020	Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19	Synthesis and Evaluation of 4-Hydroxycoumarin Imines as Inhibitors of Class II Myosins.
AID1506920	Apparent permeability from apical to basolateral side in human Caco2 cells assessed as drug recovery at 10 uM after 60 mins by HPLC-MS/MS analysis	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Improved synthesis and comparative analysis of the tool properties of new and existing D-ring modified (S)-blebbistatin analogs.
AID1453495	Inhibition of F-actin activated rabbit full length myosin 2 ATPase activity after 1 hr by CytoPhos reagent based assay	2017	Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13	Insights into the myosin II inhibitory potency of A-ring-modified (S)-blebbistatin analogs.
AID1693701	Cardiotoxicity in medaka embryo post hatching 24 hrs assessed as reduction in heart beat at 10 uM measured after 1 hr	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	In vitro and in vivo effects of inhibitors on actin and myosin.
AID1360404	Cytotoxicity against F11-hTERT cells (unknown origin) assessed as cell death at 200 uM after 3 hrs relative to control	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives.
AID1676132	Inhibition of actin-activated porcine heart muscle myosin 2	2020	Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19	Synthesis and Evaluation of 4-Hydroxycoumarin Imines as Inhibitors of Class II Myosins.
AID1360396	Steady state aqueous solubility of the compound in 10 % DMSO buffer up to 240 mins	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives.
AID1402185	Activation of actin-stimulated rabbit skeletal muscle myosin S1 fragment ATPase activity at 100 uM after 10 mins by spectrophotometric analysis relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design and synthesis of sulfonamidophenylethylureas as novel cardiac myosin activator.
AID1506918	Apparent permeability from apical to basolateral side in human Caco2 cells at 10 uM after 60 mins by HPLC-MS/MS analysis	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Improved synthesis and comparative analysis of the tool properties of new and existing D-ring modified (S)-blebbistatin analogs.
AID1360410	Cytotoxicity against human MIAPaCa2 cells assessed as cell death at 400 uM after 24 hrs	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives.
AID1577036	Activation of bovine cardiac actin thin filament complex-stimulated myosin S1 ATPase activity assessed as inorganic phosphate liberated at 10 uM incubated for 10 mins in presence of ATP by spectrophotometry relative to control	2019	Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18	Design and synthesis of sulfonamidophenylethylamides as novel cardiac myosin activator.
AID1360403	Cytotoxicity against F11-hTERT cells (unknown origin) assessed as cell death at 200 uM after 24 hrs relative to control	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives.
AID1360408	Toxicity in Dictyostelium discoideum assessed as mortality at 20 uM after 3 days relative to control	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives.
AID1676134	Inhibition of actin-activated bovine heart muscle myosin 2 assessed as phosphate level incubated for 6 to 24 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19	Synthesis and Evaluation of 4-Hydroxycoumarin Imines as Inhibitors of Class II Myosins.
AID1452466	Activation of actin-stimulated rabbit psoas skeletal muscle myosin S1 fragment ATPase activity at 100 uM after 10 mins by spectrophotometric analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1498827	Activation of actin-stimulated chicken gizzard smooth muscle myosin S1 fragment ATPase activity at 100 uM after 10 mins by spectrophotometric analysis relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	Exploration of diphenylalkyloxadiazoles as novel cardiac myosin activator.
AID1577040	Activation of myosin ATPase activity in Sprague-Dawley rat ventricular myocytes assessed as ventricular cell shortening by measuring change in ventricular cell contractility by electrophysiology	2019	Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18	Design and synthesis of sulfonamidophenylethylamides as novel cardiac myosin activator.
AID1452467	Activation of actin-stimulated chicken gizzard smooth muscle myosin S1 fragment ATPase activity at 100 uM after 10 mins by spectrophotometric analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure.
AID1506916	Potency index, ratio of (S)-blebbistatin (S)-1 IC50 to compound IC50 for inhibition of rabbit full length skeletal muscle myosin 2 ATPase activity by CytoPhos reagent based ATPase assay	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Improved synthesis and comparative analysis of the tool properties of new and existing D-ring modified (S)-blebbistatin analogs.
AID1693702	Cardiotoxicity in medaka embryo post hatching 24 hrs assessed as reduction in heart beat at 17.5 uM measured after 1 hr	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	In vitro and in vivo effects of inhibitors on actin and myosin.
AID1506924	Photostability of the compound in DMSO/H20 (1:1) solvent assessed as half life for compound degradation at 100 to 600 uM under irradiation at 390 to 470 nm by HPLC analysis	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Improved synthesis and comparative analysis of the tool properties of new and existing D-ring modified (S)-blebbistatin analogs.
AID1360413	Cytotoxicity against human PANC1 cells assessed as cell death at 400 uM after 24 hrs	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives.
AID1693690	Inhibition of rabbit muscle G-actin polymerization assessed as polymerized G-actin level at 25 uM incubated for 15 mins by spectrophotometric analysis (Rvb = 100 %)	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	In vitro and in vivo effects of inhibitors on actin and myosin.
AID1506923	Photostability of the compound in DMSO alone solvent assessed as compound degradation at 100 to 600 uM under irradiation at 390 to 470 nm up to 90 mins by HPLC analysis	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Improved synthesis and comparative analysis of the tool properties of new and existing D-ring modified (S)-blebbistatin analogs.
AID1360405	Cytotoxicity against human Fem-X cells assessed as cell death at 200 uM after 24 hrs relative to control	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives.
AID1676135	Selectivity ratio of IC50 for actin-activated bovine heart muscle myosin 2 to IC50 for actin-activated rabbit skeletal muscle myosin 2	2020	Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19	Synthesis and Evaluation of 4-Hydroxycoumarin Imines as Inhibitors of Class II Myosins.
AID1360400	Cytotoxicity against human DU145 cells assessed as cell death at 200 uM after 3 hrs relative to control	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives.
AID1506915	Inhibition of rabbit full length skeletal muscle myosin 2 ATPase activity using Pre-formed rabbit skeletal muscle F-actin filaments and ATP incubated for 1 hr by CytoPhos reagent based ATPase assay	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Improved synthesis and comparative analysis of the tool properties of new and existing D-ring modified (S)-blebbistatin analogs.
AID1693693	Induction of cell morphological changes in human MDA-MB-231 cells assessed as membrane blebbing at 2 uM measured after 30 mins by inverted microscopy	2021	Bioorganic & medicinal chemistry, 01-15, Volume: 30	In vitro and in vivo effects of inhibitors on actin and myosin.
AID1498826	Activation of actin-stimulated rabbit psoas skeletal muscle myosin S1 fragment ATPase activity at 100 uM after 10 mins by spectrophotometric analysis relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	Exploration of diphenylalkyloxadiazoles as novel cardiac myosin activator.
AID1676137	Binding affinity to skeletal myosin S1 (unknown origin) assessed as fluorescence intensity at 2 uM in presence of ATP	2020	Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19	Synthesis and Evaluation of 4-Hydroxycoumarin Imines as Inhibitors of Class II Myosins.
AID1506921	Apparent permeability from basolateral to apical side in human Caco2 cells assessed as drug recovery at 10 uM after 40 mins by HPLC-MS/MS analysis	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Improved synthesis and comparative analysis of the tool properties of new and existing D-ring modified (S)-blebbistatin analogs.
AID1676133	Inhibition of actin-activated rabbit skeletal muscle myosin 2 assessed as phosphate level incubated for 6 to 24 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19	Synthesis and Evaluation of 4-Hydroxycoumarin Imines as Inhibitors of Class II Myosins.
AID1676141	Inhibition of C57Bl6 mouse non-muscle myosin IIB assessed as reduction in action potential in mouse diaphragm at 100 uM	2020	Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19	Synthesis and Evaluation of 4-Hydroxycoumarin Imines as Inhibitors of Class II Myosins.
AID1676131	Inhibition of actin-activated rabbit skeletal muscle myosin 2	2020	Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19	Synthesis and Evaluation of 4-Hydroxycoumarin Imines as Inhibitors of Class II Myosins.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347161	Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347157	Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347169	Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	10 (55.56)	24.3611
2020's	8 (44.44)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (5.56%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	17 (94.44%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
dobutamine Dobutamine: A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.. dobutamine : A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.	2.15	1	catecholamine; secondary amine	beta-adrenergic agonist; cardiotonic drug; sympathomimetic agent
gallocatechol (-)-epigallocatechin : A flavan-3,3',4',5,5',7-hexol having (2R,3R)-configuration.	2.31	1	catechin; flavan-3,3',4',5,5',7-hexol	antioxidant; food component; plant metabolite
pentabromopseudilin pentabromopseudilin: structure given in first source	2.31	1	pyrroles	metabolite
pentachloropseudilin pentachloropseudilin: structure in first source	2.31	1
blister blebbistatin: structure in first source. blebbistatin : A pyrroloquinoline that is 1,2,3,3a-tetrahydro-H-pyrrolo[2,3-b]quinolin-4-one substituted by a hydroxy group at position 3a, a methyl group at position 6 and a phenyl group at position 1. It acts as an inhibitor of ATPase activity of non-muscle myosin II.	3.27	1	cyclic ketone; pyrroloquinoline; tertiary alcohol; tertiary alpha-hydroxy ketone	inhibitor
quercetin [no description available]	2.31	1	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
kaempferol [no description available]	2.31	1	7-hydroxyflavonol; flavonols; tetrahydroxyflavone	antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite
cytochalasin b Cytochalasin B: A cytotoxic member of the CYTOCHALASINS.. cytochalasin B : An organic heterotricyclic compound, that is a mycotoxin which is cell permeable an an inhibitor of cytoplasmic division by blocking the formation of contractile microfilaments.	2.31	1	cytochalasin; lactam; lactone; organic heterotricyclic compound	actin polymerisation inhibitor; metabolite; mycotoxin; platelet aggregation inhibitor
omecamtiv mecarbil [no description available]	3.09	4	ureas

Condition	Relationship Strength	Studies
Systolic Heart Failure [description not available]	2.15	1
Heart Failure, Systolic Heart failure caused by abnormal myocardial contraction during SYSTOLE leading to defective cardiac emptying.	2.15	1
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1

blebbistatin

Description

Cross-References

Synonyms (49)

Research Excerpts

Overview

Bioavailability

Drug Classes (2)

Protein Targets (30)

Potency Measurements

Inhibition Measurements

Biological Processes (33)

Molecular Functions (18)

Ceullar Components (12)

Bioassays (113)

Research

Studies (18)

Market Indicators

Research Demand Index: 48.34

Study Types

blebbistatin

Description

Cross-References

Synonyms (49)

Research Excerpts

Overview

Bioavailability

Drug Classes (2)

Protein Targets (30)

Potency Measurements

Inhibition Measurements

Biological Processes (33)

Molecular Functions (18)

Ceullar Components (12)

Bioassays (113)

Research

Studies (18)

Market Indicators

Research Demand Index: 48.34

Study Types

Related Drugs (9)

Related Conditions (5)